NeoImmuneTech, Inc. is a biopharmaceutical firm in clinical development, dedicated to advancing T cell-focused immunotherapeutics. The company primarily concentrates on its leading asset, NT-I7 (efineptakin alfa), an investigational, long-acting human interleukin-7 designed to boost T cell numbers and function across various oncologic and infectious diseases. This innovative approach seeks to enhance the efficacy of existing treatments like checkpoint inhibitors and CAR-T cell therapies in solid tumors, hematologic malignancies, and conditions such as acute radiation syndrome and Progressive Multifocal Leukoencephalopathy. Recent developments include positive Phase 1b data combining NT-I7 with CAR-T for large B-cell lymphoma, demonstrating improved response rates and T-cell persistence, as well as an FDA IND approval for a combination trial with BCMA CAR-T therapy for multiple myeloma. Additionally, NT-I7 has received Orphan Drug Designations for conditions including glioblastoma multiforme, pancreatic cancer, and acute radiation syndrome. Established in 2014, NeoImmuneTech maintains its headquarters in Rockville, Maryland, with operations spanning both the U.S. and Korea.